Vivitrol Improves The Likelihood Of Recovering From Alcohol Use Disorder By 26%

People in treatment for alcohol use disorder (AUD) who were discharged from treatment with a prescription for Vivitrol were 26% more likely to report abstinence. Vivitrol is a monthly naltrexone injection marketed by Alkermes. One year after leaving AUD treatment and taking Vivitrol at discharge, about 52% reported abstinence—not using any drugs or alcohol—during the last 30 days or longer. In comparison, just 41% of those in treatment for AUD who were not taking any medication at discharge reported drug or alcohol abstinence.

Abstinence at one-year post-discharge, for at least the past 30 days, was reported . . .